Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

Study Design

Type
Randomized Controlled Trial (RCT)
Sample size
n = 30
Population
60 children and adolescents with type 1 diabetes
Methods
Randomized into two groups: group I received Nigella sativa seed oil 450 mg twice daily after meals for 3 months in addition to insulin, group II received insulin alone. Echocardiographic examinations and lab measurements performed before and after treatment.
Blinding
Open-label
Duration
3 months
Funding
Unclear

Background and objective

Nigella sativa is a widely used medicinal plant with several potential therapeutic uses. This study aimed to investigate the possible beneficial cardioprotective effect of Nigella sativa in pediatric patients with type 1 diabetes mellitus.

Methods

Sixty children and adolescents with type 1 diabetes were randomized into two groups: group I (n = 30) who received Nigella sativa seed oil 450 mg twice daily after meals for 3 months in addition to insulin, and group II (n = 30) who received insulin alone. Echocardiographic examinations were performed before and after the treatment. The lipid profile, malondialdehyde, nitric oxide, tumor necrosis factor-α, transforming growth factor-β, and troponin I were also measured before and after Nigella sativa treatment.

Results

After 3 months of Nigella sativa administration, group I had significantly lower cholesterol and low-density lipoprotein-cholesterol, malondialdehyde, nitric oxide, tumor necrosis factor-α, transforming growth factor-β, and troponin I levels compared with their pretreatment levels and compared with group II. In addition, group I had a significantly higher left ventricular E'/A' ratio and two-dimensional left ventricular global longitudinal strain (2D-LV GLS) compared with baseline values and compared with group II after treatment.

Conclusions

Nigella sativa can improve subclinical left ventricular dysfunction in pediatric patients with type 1 diabetes mellitus.

Clinical trial registration

this clinical trial was registered at www.pactr.org with ID: PACTR202302478939306.

Research Insights

  • group I had a significantly higher left ventricular E'/A' ratio ... compared with baseline values and compared with group II after treatment

    Effect
    Beneficial
    Effect size
    Small
    Dose
    450 mg twice daily after meals for 3 months
  • group I had a significantly higher ... two-dimensional left ventricular global longitudinal strain (2D-LV GLS) compared with baseline values and compared with group II after treatment

    Effect
    Beneficial
    Effect size
    Small
    Dose
    450 mg twice daily after meals for 3 months
  • group I had significantly lower ... low-density lipoprotein-cholesterol ... compared with their pretreatment levels and compared with group II

    Effect
    Beneficial
    Effect size
    Moderate
    Dose
    450 mg twice daily after meals for 3 months
  • group I had significantly lower ... malondialdehyde ... levels compared with their pretreatment levels and compared with group II

    Effect
    Beneficial
    Effect size
    Small
    Dose
    450 mg twice daily after meals for 3 months
  • group I had significantly lower ... nitric oxide ... levels compared with their pretreatment levels and compared with group II

    Effect
    Beneficial
    Effect size
    Small
    Dose
    450 mg twice daily after meals for 3 months
  • group I had significantly lower cholesterol ... compared with their pretreatment levels and compared with group II

    Effect
    Beneficial
    Effect size
    Moderate
    Dose
    450 mg twice daily after meals for 3 months
  • group I had significantly lower ... transforming growth factor-β ... levels compared with their pretreatment levels and compared with group II

    Effect
    Beneficial
    Effect size
    Small
    Dose
    450 mg twice daily after meals for 3 months
  • group I had significantly lower ... troponin I ... levels compared with their pretreatment levels and compared with group II

    Effect
    Beneficial
    Effect size
    Small
    Dose
    450 mg twice daily after meals for 3 months
  • group I had significantly lower ... tumor necrosis factor-α ... levels compared with their pretreatment levels and compared with group II

    Effect
    Beneficial
    Effect size
    Small
    Dose
    450 mg twice daily after meals for 3 months
Back to top